224 related articles for article (PubMed ID: 17194570)
1. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains.
Treyaprasert W; Schmidt S; Rand KH; Suvanakoot U; Derendorf H
Int J Antimicrob Agents; 2007 Mar; 29(3):263-70. PubMed ID: 17194570
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
Liu P; Rand KH; Obermann B; Derendorf H
Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
[TBL] [Abstract][Full Text] [Related]
3. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
Knudsen JD
Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
[TBL] [Abstract][Full Text] [Related]
6. [Antibiotic resistance: an always present problem].
Debbia EA
Recenti Prog Med; 1999 Oct; 90(10):505-9. PubMed ID: 10592734
[No Abstract] [Full Text] [Related]
7. [The postantibiotic effect of azithromycin on respiratory pathogens].
Diculencu D; Andrews JM; Boswell FJ; Wise R
Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):128-34. PubMed ID: 9455450
[TBL] [Abstract][Full Text] [Related]
8. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment.
Dorfman MS; Wagner RS; Jamison T; Bell B; Stroman DW
Adv Ther; 2008 Mar; 25(3):208-17. PubMed ID: 18369536
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
Girard D; Finegan SM; Dunne MW; Lame ME
J Antimicrob Chemother; 2005 Aug; 56(2):365-71. PubMed ID: 16002421
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study.
Jacobs MR; Bajaksouzian S; Windau A; Good CE; Lin G; Pankuch GA; Appelbaum PC
Clin Lab Med; 2004 Jun; 24(2):503-30. PubMed ID: 15177851
[TBL] [Abstract][Full Text] [Related]
11. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey.
Gonullu N; Catal F; Kucukbasmaci O; Ozdemir S; Torun MM; Berkiten R
Chemotherapy; 2009; 55(3):161-7. PubMed ID: 19390189
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
13. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
14. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
Sevillano D; Alou L; Aguilar L; Echevarría O; Giménez MJ; Prieto J
J Antimicrob Chemother; 2006 Jun; 57(6):1128-33. PubMed ID: 16617063
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.
Beekmann SE; Heilmann KP; Richter SS; García-de-Lomas J; Doern GV;
Int J Antimicrob Agents; 2005 Feb; 25(2):148-56. PubMed ID: 15664485
[TBL] [Abstract][Full Text] [Related]
16. Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.
Destache CJ; Pakiz CB; Kersting K
Pharmacotherapy; 1997; 17(5):985-9. PubMed ID: 9324186
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
18. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial resistance among Streptococcus pneumoniae and Haemophilus influenzae isolates in the United Arab Emirates: 2004-2006.
Senok A; Al-Zarouni M; Al-Najjar J; Nublusi A; Panigrahi D
J Infect Dev Ctries; 2007 Dec; 1(3):296-302. PubMed ID: 19734608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
